Skip to Main Content

Paper Details

Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
Front Oncol
2
2023
Author NameAffiliation
Rohit BoseHelen Diller Family Cancer Center, University of California San Francisco
Rahul AggarwalHelen Diller Family Cancer Center, University of California San Francisco
Lawrence FongHelen Diller Family Cancer Center, University of California San Francisco
Eric J SmallHelen Diller Family Cancer Center, University of California San Francisco
Jonathan ChouHelen Diller Family Cancer Center, University of California San Francisco
  • 1 - 5

Datasets